Liang Ian, Brennan Sarah, Girgis Christian, Hayden Amy, Moujaber Tania, Turner Sandra, Vasista Anuradha, Grossmann Mathis, Wong Peter K K
Institute of Rheumatology and Orthopaedics, Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia.
Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.
Cancer Med. 2025 May;14(9):e70873. doi: 10.1002/cam4.70873.
Survival of patients with prostate and breast cancer, the commonest cancer in men and women, respectively, has markedly improved with advances in early diagnosis, treatment and multi-disciplinary care by the oncology and surgical community. However, the use of increasingly potent endocrine therapies may cause bone loss, resulting in secondary osteoporosis.
This review summarises the current management of cancer treatment-induced bone loss in this group of patients at high risk of osteoporotic fractures with their attendant morbidity and mortality.
Bone health is an increasingly important part of cancer survivorship. Radiation and medical oncologists, urologists, bone health experts, general practitioners, healthcare professional bodies and bone health and cancer consumer organisations should increase awareness of the potential adverse effect of endocrine therapy on bone health. While this should never delay cancer treatment, bone health should be part of routine care for men and women receiving endocrine therapy for prostate and breast cancer.
前列腺癌和乳腺癌分别是男性和女性中最常见的癌症，随着肿瘤学和外科领域在早期诊断、治疗及多学科护理方面取得的进展，这两类癌症患者的生存率有了显著提高。然而，使用日益强效的内分泌疗法可能会导致骨质流失，进而引发继发性骨质疏松症。
本综述总结了当前针对这组有骨质疏松性骨折高风险及其相关发病率和死亡率的患者，对癌症治疗引起的骨质流失的管理方法。
骨骼健康在癌症幸存者护理中变得越来越重要。放射肿瘤学家、医学肿瘤学家、泌尿科医生、骨骼健康专家、全科医生、医疗保健专业机构以及骨骼健康和癌症患者组织应提高对内分泌疗法对骨骼健康潜在不良影响的认识。虽然这绝不应延误癌症治疗，但骨骼健康应成为接受前列腺癌和乳腺癌内分泌治疗的男性和女性常规护理的一部分。
